ACOG PRACTICE BULLETIN

Clinical Management Guidelines for Obstetrician–Gynecologists

Nausea and Vomiting of Pregnancy

Nausea and vomiting of pregnancy is a common condition that affects the health of a pregnant woman and her fetus. It can diminish a woman's quality of life and also significantly contributes to health care costs and time lost from work (1, 2). Because morning sickness is common in early pregnancy, the presence of nausea and vomiting of pregnancy may be minimized by obstetricians, other obstetric care providers, and pregnant women and, thus, undertreated (1). Furthermore, some women do not seek treatment because of concerns about the safety of medications (3). Once nausea and vomiting of pregnancy progresses, it can become more difficult to control symptoms. Treatment in the early stages may prevent more serious complications, including hospitalization (4). Safe and effective treatments are available for more severe cases, and mild cases of nausea and vomiting of pregnancy may be resolved with lifestyle and dietary changes. The woman's perception of the severity of her symptoms plays a critical role in the decision of whether, when, and how to treat nausea and vomiting of pregnancy. Nausea and vomiting of pregnancy should be distinguished from nausea and vomiting related to other causes. The purpose of this document is to review the best available evidence about the diagnosis and management of nausea and vomiting of pregnancy.

Background

Definition and Incidence

Nausea and vomiting of pregnancy is a common condition with prevalence rates for nausea of 50–80% and for vomiting and retching of 50% (5). Recurrence of nausea and vomiting of pregnancy with subsequent pregnancies ranges from 15–81% (6). One study has attempted to categorize nausea and vomiting of pregnancy into degrees of severity by assessing the duration of nausea and vomiting each day (from less than 1 hour in mild cases to more than 6 hours in severe cases) and the amount of vomiting and retching per day (up to two times for mild and moderate nausea and vomiting of pregnancy and more than five times in severe cases) (1). However, these categories were not compared against quality of life measures. A published, validated nausea and vomiting of pregnancy severity index known as the mother risk pregnancy-unique quantification of emesis and nausea (PUQE) assesses the severity of nausea and vomiting of pregnancy during the first trimester (7). Scores from

the PUQE index are associated with quality of life measurements, which demonstrates the clinical utility of the index (Table 1) (8). The woman's perception of the severity of her symptoms, her desire for treatment, and the potential effect of treatment on her fetus all influence clinical decision making. Early treatment of nausea and vomiting of pregnancy may be beneficial to prevent progression to hyperemesis gravidarum.

No single accepted definition of hyperemesis gravidarum exists. It is a clinical diagnosis of exclusion based on a typical presentation in the absence of other diseases that could explain the findings (9). The most commonly cited criteria include persistent vomiting not related to other causes, a measure of acute starvation (usually large ketonuria), and some discrete measure of weight loss, most often at least 5% of prepregnancy weight (10). Electrolyte, thyroid, and liver abnormalities also may be present. From an epidemiologic perspective, hyperemesis gravidarum appears to represent the extreme end of the spectrum of nausea and vomiting of pregnancy (11). The incidence of hyperemesis gravidarum is

Table 1. Modified Pregnancy-Unique Quantification of Emesis and Nausea ⇐

Circle the answer that best suits your situation from the beginning of your pregnancy.

1. On average in a day, for how long do you feel nauseated or sick to your stomach?

Not at all	1 hr or less	2–3 hr	4–6 hr	More than 6 hr
(1)	(2)	(3)	(4)	(5)

2. On average in a day, how many times do you vomit or throw up?

7 or more times	5–6 times	3–4 times	1–2 times	I did not throw up
(5)	(4)	(3)	(2)	(1)

3. On average in a day, how many times do you have retching or dry heaves without bringing anything up?

None	1–2 times	3–4 times	5–6 times	7 or more times
(1)	(2)	(3)	(4)	(5)

Total score (sum of replies to 1, 2, and 3): mild NVP, 6 or less; moderate NVP, 7–12; severe NVP, 13 or more.

Abbreviation: NVP, nausea or vomiting of pregnancy.

Reprinted from Lacasse A, Rey E, Ferreira E, Morin C, Berard A. Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am J Obstet Gynecol 2008;198:71.e1–7.

approximately 0.3–3% of pregnancies (5). The reported incidence varies because of different diagnostic criteria and ethnic variation in study populations. Hyperemesis gravidarum is the most common indication for admission to the hospital during the first part of pregnancy and is second only to preterm labor as the most common reason for hospitalization during pregnancy (12, 13).

Differential Diagnosis

The timing of the onset of nausea and vomiting is important—symptoms of nausea and vomiting of pregnancy manifest before 9 weeks of gestation in virtually all affected women. When a patient experiences nausea and vomiting for the first time after 9 weeks of gestation, other conditions should be carefully considered in the differential diagnosis (see Box 1). A history of a chronic condition associated with nausea and vomiting that predates pregnancy should be sought (eg, cholelithiasis or diabetic gastroparesis). Rare cases of hyperemesis gravidarum related to a Mendelian disorder of hormone-receptor interaction (14) and mitochondrial disorders (15) suggest that at least some portion of hyperemesis is caused by discrete disease states that are unmasked or exacerbated in pregnancy.

A number of physical findings point to conditions other than nausea and vomiting of pregnancy as the cause of the nausea and vomiting. For example, abdominal pain or tenderness other than mild epigastric discomfort after retching is not a prominent characteristic of nausea and vomiting of pregnancy. Fever and headache are not pres-

ent in nausea and vomiting of pregnancy. An abnormal neurologic examination suggests a primary neurologic disorder as the cause of the nausea and vomiting, although it rarely may be encountered as a consequence of severe nausea and vomiting of pregnancy (eg, thiamine-deficient encephalopathy or central pontine myelinolysis). Although biochemical hyperthyroidism may be seen with hyperemesis gravidarum, a palpable goiter is not due to nausea and vomiting of pregnancy. If a goiter is present, primary thyroid disease should be suspected. The findings of no prior history of thyroid disease, no evidence of Graves disease (such as goiter), and a self-limited disorder with symptoms of emesis, favor the diagnosis of gestational transient thyrotoxicosis and routine thyroid tests are not needed (16, 17). However, in patients with hyperemesis gravidarum in whom thyroid function tests are obtained, results may demonstrate a hyperthyroxinemia or gestational transient thyrotoxicosis. This is generally limited to the first half of pregnancy and may be characterized by elevated free T4 and suppressed serum thyroid stimulating hormone. The appropriate management of abnormal maternal thyroid tests attributable to gestational transient thyrotoxicosis, or hyperemesis gravidarum, or both, includes supportive therapy, and antithyroid drugs are not recommended (18).

Etiology and Risk Factors

The etiology of nausea and vomiting of pregnancy is unknown. Various theories have been proposed, including a hormonal stimulus, evolutionary adaptation, and psychologic predisposition (19, 20).

Hormones

Human Chorionic Gonadotropin

Because of the close temporal relationship between peak human chorionic gonadotropin (hCG) concentrations and peak symptoms of nausea and vomiting of pregnancy, hCG arising from the placenta has been considered a likely candidate for the emetogenic stimulus. The role of hCG also is suggested by the fact that almost all studies of thyroid hormones in pregnancy show an association between transient hyperthyroidism and nausea and vomiting of pregnancy. It has been conclusively shown that hCG is a thyroid stimulator of pregnancy (21), but because hyperthyroidism itself rarely causes vomiting, this finding has focused attention back on hCG and its relationship to nausea and vomiting of pregnancy. Among the many studies comparing nonthyroidal hormone concentrations in women with and without vomiting, only hCG and estradiol have been found to have an association. The failure of some studies to show an association of nausea and vomiting of pregnancy with hCG may be related to the varying biologic activity of different hCG isoforms as well as variation in the susceptibility of the individual woman to any emetogenic stimulus. The extent of the hCG stimulus may be modified by placental conditions that increase its concentration (eg, multiple gestation or molar gestation) and by hormone-receptor interactions modifying the effect of the hormone.

Estrogen

Another hormone known to influence nausea and vomiting of pregnancy is estrogen. Nausea and vomiting of pregnancy is more common when estradiol levels are increased and less common when estradiol levels are decreased (22, 23). Cigarette smoking is associated with lower levels of hCG and estradiol (24), and numerous studies have shown that smokers are less likely to have hyperemesis gravidarum. Estrogen in the combined oral contraceptive pill was shown to induce nausea and vomiting in a dose-related fashion (25). Women with nausea and vomiting after estrogen exposure were more likely to have nausea and vomiting of pregnancy than women who did not demonstrate such sensitivity to estrogen (26).

Evolutionary Adaptation

It also has been posited that nausea and vomiting of pregnancy is an evolutionary adaptation that developed to protect the woman and her fetus from foods that might be potentially dangerous (27). This theory may explain the temporary aversions to tastes and smells that pregnant women experience. Proponents of the adaptation theory suggest nausea and vomiting of pregnancy is a healthy,

protective response to pregnancy. Clinical application of this theory, however, may lead to undertreatment of women whose quality of life is diminished by nausea and vomiting of pregnancy.

Psychologic Predisposition

It is likely that the concept that nausea and vomiting of pregnancy reflects a psychologic disorder has impeded progress toward a greater understanding of the condition (28). Experts continue to debate whether psychologic illness is a predisposing factor for or a complication of hyperemesis gravidarum. The question of whether certain personality types or specific psychologic disorders predispose someone to hyperemesis gravidarum has been raised in the literature for many years. Small case–control trials have noted that neither de novo nor recurrent hyperemesis gravidarum is associated with any underlying psychiatric condition when compared with pregnant women without nausea and vomiting of pregnancy (29, 30). A review of psychologic theories proposed to explain the etiology of nausea and vomiting of pregnancy concluded that the evidence that nausea and vomiting of pregnancy is caused by a conversion disorder or an abnormal response to stress is "questionable at best" (31).

Risk Factors

Women with increased placental mass (eg, advanced molar gestation or multiple gestation) are at increased risk of hyperemesis gravidarum. Other risk factors include a history of motion sickness, migraine headaches, a family history (genetics), or a history of hyperemesis gravidarum in a previous pregnancy (26). One study found that approximately two thirds of women who described their vomiting as severe in one pregnancy had similar symptoms in the next pregnancy, and one half of women who described their symptoms as mild in one pregnancy found that the symptoms worsened in the next (32). Daughters and sisters of women who had hyperemesis gravidarum are more likely to have the same problem, as are women carrying female fetuses (33).

Maternal Effects of Nausea and Vomiting of Pregnancy

Although death from nausea and vomiting of pregnancy is reported rarely today, significant morbidity, such as Wernicke encephalopathy, splenic avulsion, esophageal rupture, pneumothorax, and acute tubular necrosis, have been reported (34–42). Wernicke encephalopathy (caused by vitamin B_1 deficiency) related to hyperemesis

gravidarum has been associated with maternal death or permanent neurologic disability (35–37).

In addition to increased hospital admissions (43, 44), some women experience significant psychosocial morbidity caused by nausea and vomiting of pregnancy, resulting in a decision for pregnancy termination. A systematic review of psychological morbidity in relation to hyperemesis gravidarum did demonstrate significantly higher depression and anxiety scale scores in women with the condition. However, these findings are limited by the high level of heterogeneity between studies (45).

Fetal Effects of Nausea and Vomiting of Pregnancy

The severity of nausea and vomiting dictates its effect on the embryo and fetus. With mild or moderate vomiting, there is little apparent effect on pregnancy outcome. Studies have documented a lower rate of miscarriage among women with nausea and vomiting of pregnancy and hyperemesis gravidarum when compared with controls (46). This result is thought to be related to robust placental synthesis in a healthy pregnancy rather than a protective effect of vomiting. No significant association of hyperemesis gravidarum with congenital anomalies has been demonstrated (47). The outcome most frequently examined is the incidence of low birth weight (LBW). However, some studies have identified no increase in LBW with nausea and vomiting of pregnancy (11, 48–50). Conversely, a systematic review and meta-analysis of women with hyperemesis gravidarum showed a higher incidence of LBW and small-for-gestational-age infants and premature infants (47). However, no association of hyperemesis gravidarum and perinatal or neonatal mortality has been demonstrated in large retrospective cohorts (51). Although little may be known about the long-term health of children or women after pregnancies complicated by hyperemesis gravidarum, it is appropriate to reassure patients that the presence of nausea and vomiting of pregnancy and even hyperemesis gravidarum most often portends well for pregnancy outcome.

Clinical Considerations and Recommendations

In many studies, patients with hyperemesis gravidarum are grouped with those with other degrees of nausea and vomiting of pregnancy. Because it is likely that hyperemesis gravidarum is part of the continuum of nausea and vomiting of pregnancy, the following discussion focuses on treatment for all stages of this condition.

▶ Are nonpharmacologic therapies effective for the treatment of nausea and vomiting of pregnancy?

Treatment of nausea and vomiting of pregnancy begins with prevention. Two studies found that women who were taking a multivitamin at the time of fertilization were less likely to need medical attention for vomiting (52, 53). Although the biological basis of this observation is unclear, the authors speculate that this may have been because of a generalized optimization of nutritional status or because increasing levels of vitamin B_6 (pyridoxine) may reduce vomiting in some women (52, 53). Therefore, the standard recommendation to take prenatal vitamins for 1 month before pregnancy may reduce the incidence and severity of nausea and vomiting of pregnancy (54).

There is little published evidence regarding the efficacy of dietary changes for prevention or treatment of nausea and vomiting of pregnancy. Frequent, small meals every 1–2 hours to avoid a full stomach often are recommended (55). Other dietary modifications that may be helpful include avoiding spicy or fatty foods; eliminating supplemental iron and substituting folic acid for iron-containing prenatal vitamins; and eating bland or dry foods, high-protein snacks, and crackers in the morning before arising (56). A small study showed that protein meals were more likely to alleviate nausea and vomiting of pregnancy than carbohydrate or fatty meals (57). The woman's perception of the severity of her symptoms and her desire for treatment are influential in clinical decision making. Common recommendations to alleviate initial signs of nausea and vomiting of pregnancy include rest and avoidance of sensory stimuli such as odors, heat, humidity, noise, and flickering lights that may provoke symptoms.

Treatment of nausea and vomiting of pregnancy with ginger has shown some beneficial effects in reducing nausea symptoms and can be considered as a nonpharmacologic option. Systematic reviews of randomized controlled and nonrandomized controlled trials have found that ginger was associated with improvement in nausea; however, none of the trials showed benefit in reducing vomiting (5, 58, 59).

Acupressure, acupuncture, or electrical nerve stimulation (acustimulation) at the P6 or Neiguan point (located three finger breadths below the wrist on the inside of the wrist in between the two tendons) has been studied for nausea and vomiting of pregnancy with conflicting results. Most studies report a benefit, but many have significant methodologic flaws, and the two largest, best-designed studies showed no benefit compared with sham stimulation (60). Two systematic reviews found limited benefit with P6 acupressure but no benefit in P6 acupuncture or nerve stimulation in the treatment of nausea and vomiting of pregnancy (5, 59).

▶ Are pharmacologic therapies effective for treatment of nausea and vomiting of pregnancy?

Effective pharmacologic therapy is available, but agreement on the appropriate timing of antiemetic therapy has changed in recent years. Early treatment of nausea and vomiting of pregnancy is recommended to prevent progression to hyperemesis gravidarum. In a randomized controlled trial (RCT) of women with a history of severe nausea and vomiting of pregnancy in their previous gestation, the initiation of antiemetic therapy before the onset of nausea and vomiting symptoms was associated with a reduction in the severity of nausea and vomiting of pregnancy compared with initiation of a combination of doxylamine and vitamin B_6 (pyridoxine) after the onset of symptoms (61).

When women with nausea and vomiting of pregnancy are unable to tolerate oral medications, other administration modalities may be beneficial. Besides oral and intravenous routes, there are other options of delivery for several medications used to treat nausea and vomiting of pregnancy. Some of the phenothiazine products (promethazine and prochlorperazine) are available as rectal suppositories. The serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are available as an oral dissolvable tablet (ondansetron) or a transdermal patch (granisetron) formulation.

There is limited evidence regarding the clinical efficacy of the use of continuous subcutaneous microinfusion pumps to administer metoclopramide or ondansetron for the treatment of nausea and vomiting of pregnancy (62, 63). Moreover, adverse effects with the use of continuous subcutaneous pumps were seen in 11–31% of selected patients (62). At present, subcutaneous microinfusion pumps of these antiemetic therapies do not appear to be cost effective when compared with conventional treatment alternatives, including periodic hospitalization (64).

Although no single approach has been proved to be more effective than the other, Figure 1 depicts a hierarchy of therapeutic interventions that balances safety and efficacy. As with all medications, the potential risks, benefits, adverse effects and costs should be weighed in each case. Care should be exercised if multiple antiemetic medications are used simultaneously. Parallel use of a dopamine antagonist (such as metoclopramide) and various phenothiazine medications (eg, promethazine, prochlorperazine, or chlorpromazine) may result in an

First Line Therapy: Nonpharmacologic options
Convert prenatal vitamin to folic acid supplement only
Ginger capsules 250 mg four times daily
Consider P6 acupressure with wrist bands

↓ Persistent symptoms

Pharmacologic Options*
Vitamin B_6 (pyridoxine) 10–25 mg orally (either taken alone or in combination with Doxylamine[†] 12.5 mg orally), 3 or 4 times per day. Adjust schedule and dose according to severity of patient's symptoms.
OR
Vitamin B_6 (pyridoxine) 10 mg/Doxylamine 10 mg combination product, two tablets orally at bedtime initially, up to four tablets per day (one tablet in the morning, one tablet in midafternoon, and two tablets at bedtime)
OR
Vitamin B_6 (pyridoxine) 20 mg/Doxylamine 20 mg combination product, one tablet orally at bedtime initially, up to two tablets per day (one tablet in the morning and one tablet at bedtime)

↓ Persistent symptoms

Add the following:
(presented here in alphabetical order)
Dimenhydrinate, 25–50 mg every 4–6 hours, orally as needed
(not to exceed 200 mg per day if patient also is taking doxylamine)
OR
Diphenhydramine, 25–50 mg orally every 4–6 hours
OR
Prochlorperazine, 25 mg every 12 hours rectally
OR
Promethazine, 12.5–25 mg every 4–6 hours, orally or rectally

No dehydration	Dehydration

No dehydration → Persistent symptoms

Add any of the following:
(presented here in alphabetical order)
Metoclopramide, 5–10 mg every 6–8 hours, orally or intramuscularly
OR
Ondansetron, 4 mg orally every 8 hours
OR
Promethazine, 12.5–25 mg every 4–6 hours, orally, rectally, or intramuscularly
OR
Trimethobenzamide, 200 mg every 6–8 hours, intramuscularly

Dehydration →

Intravenous fluid replacement[‡]

↓ Persistent symptoms

Add any of the following:
(presented here in alphabetical order)
Dimenhydrinate, 50 mg (in 50 mL saline, over 20 min) every 4–6 hours, intravenously
OR
Metoclopramide, 5–10 mg every 8 hours, intravenously
OR
Ondansetron, 8 mg, over 15 minutes, every 12 hours, intravenously
OR
Promethazine, 12.5–25 mg every 4–6 hours, intravenously

↓ Persistent symptoms

Add the following:
(presented here in alphabetical order)
Chlorpromazine 25–50 mg intravenously or intramuscularly every 4–6 hours or 10–25 mg orally every 4 to 6 hours.
OR
Methylprednisolone 16 mg every 8 hours, orally or intravenously, for 3 days. Taper over 2 weeks to lowest effective dose. If beneficial, limit total duration of use to 6 weeks.

Figure 1. Algorithm of therapeutic treatment of nausea and vomiting of pregnancy (if no improvement, proceed to next step in algorithm). This algorithm assumes other causes of nausea and vomiting have been ruled out. At any step, consider enteral nutrition if dehydration or persistent weight loss is noted. *Some antiemetic medications have only been approved by the U.S. Food and Drug Administration for use in nonpregnant patients; however, off-label use is common. Obstetricians and other obstetric care providers should counsel patients and document such discussions accordingly. Care should be exercised if multiple antiemetic medications are used simultaneously. Parallel use of some medications (see text) may result in an increased risk of adverse effects. [†]In the United States, doxylamine is available as the active ingredient in some over-the-counter sleep aids; one half of a scored 25-mg tablet can be used to provide a 12.5-mg dose of doxylamine. [‡]Thiamine, intravenously, 100 mg with the initial rehydration fluid and 100 mg daily for the next 2–3 days (followed by intravenous multivitamins), is recommended for women who require intravenous hydration and have vomited for more than 3 weeks to prevent a rare but serious maternal complication, Wernicke encephalopathy. (Modified from Levichek Z, Atanackovic G, Oepkes D, Maltepe C, Einarson A, Magee L, et al. Nausea and vomiting of pregnancy. Evidence-based treatment algorithm. Can Fam Physician 2002;48:267–8, 277.) ⇐

increased risk of extrapyramidal effects (eg, tardive dyskinesia) or rarely neuroleptic malignant syndrome (a life-threatening reaction, including high fever, confusion, rigid muscles, and symptoms of autonomic nervous system instability). The serotonin 5-HT3 inhibitor (eg, ondansetron) when used with phenothiazine medications (such as chlorpromazine) may result in a potential cardiac risk of QT interval prolongation.

Vitamin B_6 (Pyridoxine) With or Without Doxylamine

Treatment of nausea and vomiting of pregnancy with vitamin B_6 (pyridoxine) alone or vitamin B_6 (pyridoxine) plus doxylamine in combination is safe and effective and should be considered first-line pharmacotherapy. Randomized controlled trials have evaluated vitamin B_6 (pyridoxine) alone for treatment of varying degrees of severity of nausea and vomiting of pregnancy (65, 66). One study compared a vitamin B_6 (pyridoxine) dosage of 25 mg every 8 hours with placebo and found a significant reduction in severe vomiting but minimal effect on mild vomiting (65). A larger study (N=342) used a vitamin B_6 (pyridoxine) dosage of 10 mg every 8 hours and found a reduction in nausea and vomiting compared with placebo (66). A systematic review of RCTs found that it was difficult to determine the effectiveness of vitamin B_6 (pyridoxine) in relieving nausea and vomiting symptoms, given the paucity of high-quality evidence (5). In contrast, a recent systematic review of RCTs and non-RCTs found that vitamin B_6 (pyridoxine) was associated with improvement in mild nausea and vomiting symptoms (59).

When the combination of vitamin B_6 (pyridoxine) (10 mg) plus doxylamine (10 mg) was available in the United States (from 1958 to 1983), an estimated 25–30% of all pregnant women received this agent. Analysis of hospital admissions during this period suggests that the ready availability of vitamin B_6 (pyridoxine) plus doxylamine for the treatment of the spectrum of nausea and vomiting of pregnancy was associated with fewer hospital admissions for hyperemesis gravidarum (44). Although some initial studies suggested an association of the combination of vitamin B_6 (pyridoxine) plus doxylamine with birth defects, large epidemiologic studies demonstrated no measurable teratogenic effects (67). However, despite continued U.S. Food and Drug Administration (FDA) approval of this medication, the manufacturer ceased worldwide production of the combination vitamin B_6 (pyridoxine) plus doxylamine product because of liability costs. After the combination was removed from the U.S. market in 1983, use of all antiemetics to treat nausea and vomiting of pregnancy diminished considerably, and hospitalization rates for nausea and vomiting of pregnancy increased (44, 68).

First in 2013, and then an extended-release version in 2016, the combination vitamin B_6 (pyridoxine) plus doxylamine medications were approved by the FDA in the United States for treatment of nausea and vomiting of pregnancy in women who do not respond to dietary and lifestyle changes (69). A multicenter RCT of a combination medication of vitamin B_6 (pyridoxine) plus doxylamine for nausea and vomiting of pregnancy found a significant improvement in nausea and vomiting symptoms compared with placebo (70). A secondary analysis of this RCT found that the vitamin B_6 (pyridoxine) plus doxylamine medication was well tolerated in women with nausea and vomiting of pregnancy and was not associated with increased adverse maternal effects (71). Central nervous system adverse effects (sleepiness, tiredness, or drowsiness, or all three) occurred in 28% of women who took the combined medication. The fetal safety of the combination vitamin B_6 (pyridoxine) plus doxylamine medication has been demonstrated in numerous epidemiologic studies (72).

Dopamine Antagonists

Several dopamine antagonists have been described in the medical literature for treatment of nausea and vomiting of pregnancy, such as metoclopramide and various phenothiazine medications (promethazine, prochlorperazine, or chlorpromazine). These medications may be given orally, rectally, intramuscularly, or intravenously. Relief of nausea and vomiting has been demonstrated in large groups of patients (73). A double-blind RCT of intravenous promethazine versus metoclopramide in women with hyperemesis gravidarum found that both medications had similar efficacy in reducing nausea and vomiting symptoms at 24 hours but the rates of drowsiness, dizziness, and dystonia were less with metoclopramide use (74). Adverse effects of these medications include dry mouth, drowsiness, dystonia, and sedation. Although phenothiazines were identified as a possible cause of congenital malformations in one study (75), the aggregate of studies attests to their safety (73). Metoclopramide use during pregnancy has not been shown to increase risk of congenital malformations.

Antihistamines

Antihistamines (such as dimenhydrinate and diphenhydramine) have been shown to be effective in controlling nausea and vomiting symptoms of pregnancy and

are frequently used. The efficacy of these medications in reducing nausea and vomiting of pregnancy was demonstrated in a meta-analysis of various antihistamines (73). Further, the majority of studies have shown no association of prenatal antihistamine exposure and birth defects (76). Common adverse effects include sedation, dry mouth, lightheadedness, and constipation.

Serotonin 5-hydroxytryptamine type 3 receptor antagonists

Evidence is limited on the safety or efficacy of the serotonin 5-HT3 inhibitors (eg, ondansetron) for nausea and vomiting of pregnancy; however, use appears to be increasing (77). A double-blind RCT of intravenous ondansetron versus metoclopramide in women with hyperemesis gravidarum found that both medications had similar efficacy in reducing nausea and vomiting symptoms but the rates of drowsiness, xerostomia, and persistent ketonuria at 24 hours were less with ondansetron use (78). In another randomized trial of oral ondansetron versus metoclopramide in women with severe vomiting, ondansetron was better at controlling vomiting but had a similar effect to metoclopramide in managing nausea (79). Ondansetron also was found to be more effective than the combination of doxylamine and vitamin B_6 (pyridoxine) in controlling nausea and vomiting symptoms in a small double-blind RCT of 36 women (80).

Common adverse effects of ondansetron include headache, drowsiness, fatigue, and constipation. Ondansetron can prolong the QT interval, especially in patients with underlying heart problems, hypokalemia, or hypomagnesemia (63, 81). In December 2012, the FDA announced the removal of the 32-mg single intravenous dose of ondansetron from the market because of the potential cardiac risk of QT interval prolongation leading to torsade de pointes, a potentially fatal heart rhythm. The FDA recommends that ondansetron not be given intravenously in doses greater than 16 mg. Electrolyte and electrocardiogram monitoring are recommended in patients being treated with ondansetron who have risk factors for arrhythmia, including family or personal history of prolonged QT interval, heart failure, hypokalemia, hypomagnesemia, or use of concomitant medications that lead to prolongation of the QT interval (Box 2) (82).

There are insufficient data on fetal safety with ondansetron use and further studies are warranted. A possible association of ondansetron use in the first trimester and cleft palate has been reported, but the data

---

Box 2. Contraindicated Medications for Patients Receiving Ondansetron ⇐

Examples of medications to be avoided by patients receiving ondansetron include but are not limited to the following:

- Antihistamines (hydroxyzine)
- Analgesics and sedatives (methadone, oxycodone, and chloral hydrate)
- Diuretics
- Anticholinergics
- Antiarrhythmics (amiodarone, sotalol, quinidine, procainamide, and flecainide)
- Antipsychotics (thioridazine, haloperidol, chlorpromazine, and clozapine)
- Tricyclic and tetracyclic antidepressants (amitriptyline, imipramine, and clomipramine)
- Macrolide antibiotics (erythromycin and azithromycin)
- Trazodone
- Fluoxetine
- Antimalarials (chloroquine, mefloquine, and quinine)
- Metronidazole
- Human immunodeficiency virus (HIV) protease inhibitors

---

were limited by a small sample size and potential recall-reporting bias (83). Individual studies of the association between ondansetron and congenital malformations are inconsistent, with some showing an increase in birth defects and others showing no difference (81, 84, 85). A recent systematic review of ondansetron use in early pregnancy found eight studies that were adequate for inclusion (86). Although there was a small increase in the risk of cardiac defects in two of the studies (odds ratio [OR], 2.0; 95% CI; 1.3-3.1 and OR, 1.62; 95% CI; 1.04-2.14), there was no increase in the overall rate of malformations in the ondansetron-exposed patients. Thus, although some studies have shown an increased risk of birth defects with early ondansetron use, other studies have not and the absolute risk to any fetus is low. However, women should be counseled regarding the available data, and the use of ondansetron before 10 weeks of gestation should be individualized weighing the risks and benefits.

Steroids

Several case series have suggested a benefit of corticosteroids in the treatment of hyperemesis gravidarum.

A randomized trial that compared methylprednisolone (16 mg, three times per day for 3 days, followed by a 2-week taper) with oral promethazine (25 mg, three times a day for two weeks) showed equal rates of improvement among hospitalized patients; however, readmission to the hospital within 2 weeks of discharge occurred significantly less frequently in those taking steroids (87). In contrast, a later RCT of intravenous methylprednisolone followed by a tapered dose of an oral prednisone among women hospitalized for hyperemesis gravidarum found that the use of corticosteroids did not reduce the need for rehospitalization (88). A recent systematic review of RCTs on corticosteroids for the treatment of hyperemesis gravidarum found a reduction in the rehospitalization rate but no difference in hospital admission days (89).

Three studies have confirmed an association between oral clefts and methylprednisolone use in the first trimester (90–92). The teratogenic effect is weak, probably accounting for no more than one or two cases per 1,000 treated women (93). Nevertheless, in view of this probable association, corticosteroid use for hyperemesis gravidarum should be used with caution and avoided as a first-line agent before 10 weeks of gestation. The most commonly described regimen is methylprednisolone, 48 mg daily for 3 days, given orally or intravenously (87). Patients who do not respond within 3 days are not likely to respond, and treatment should be stopped. For those who do respond, the dose may be tapered over a period of 2 weeks. For recurrent vomiting, the tapered dose may be stopped and the patient continued on the effective dose for up to 6 weeks. To limit serious maternal adverse effects, corticosteroids should not be continued beyond this period for the treatment of hyperemesis gravidarum. Treatment of severe nausea and vomiting of pregnancy or hyperemesis gravidarum with methylprednisolone may be efficacious in refractory cases; however, the risk profile of methylprednisolone suggests it should be a last-resort treatment.

▶ *Is there a role for laboratory or radiologic assessment in the diagnosis of hyperemesis gravidarum?*

An ultrasound examination may be useful in cases of severe presumed nausea and vomiting of pregnancy. It may identify a predisposing factor such as multiple gestation or molar gestation. Most patients with nausea and vomiting of pregnancy do not require laboratory evaluation, but in those with nausea and vomiting of pregnancy that is severe or persistent, laboratory assessment may help establish the differential diagnosis of hyperemesis gravidarum and assess the severity of the condition. Common laboratory abnormalities in hyper-

emesis gravidarum include increased liver enzymes (usually less than 300 units/L), serum bilirubin (less than 4 mg/dL), and serum amylase or lipase concentrations (up to five times greater than normal levels). Primary hepatitis as a cause of nausea and vomiting of pregnancy results in increased liver enzyme levels, often in the thousands; bilirubin concentrations usually are greatly increased as well. Acute pancreatitis may cause vomiting and elevated amylase concentrations, but serum amylase concentrations usually are 5–10 times greater than the elevations associated with nausea and vomiting of pregnancy. A hypochloremic metabolic alkalosis can be seen as a result of severe vomiting of any cause. Studies do show an association between higher hCG levels and the presence of hyperemesis gravidarum but the fact that hCG levels have not been standardized for the duration of pregnancy (eg, reporting them as multiple of medians) makes levels incomparable (94). Urinalysis may show elevated specific gravity, or ketonuria, or both. However, a systematic review and meta-analysis of biomarkers for the diagnosis of hyperemesis gravidarum found no association between ketonuria and the presence or severity of hyperemesis gravidarum (94). Gastric ulcer should be considered in patients with persistent hyperemesis gravidarum who are unresponsive to standard therapy and consideration should be given to test for *Helicobacter pylori* infection. Treatment with antibiotics and H2-receptor antagonists is safe in pregnancy (95, 96) and has been reported to be beneficial in case reports (97).

Hyperthyroidism itself rarely may present with significant vomiting, but in the patient who has no goiter, thyroid tests are not routinely needed to clarify the differential diagnosis unless the individual exhibits clinical signs or symptoms of hyperthyroidism (16, 17). Depending upon the definition used for hyperthyroidism in pregnancy, between 5% and 66% of patients with hyperemesis gravidarum will have suppressed thyroid-stimulating hormone levels or elevated free thyroxine concentrations (16, 98). For the patient who has no history of hyperthyroidism before pregnancy and no goiter, the hyperthyroidism of hyperemesis gravidarum can be expected to resolve by 20 weeks of gestation without specific antithyroid therapy.

▶ *When is enteral or parenteral nutrition recommended?*

Intravenous hydration should be used for the patient who cannot tolerate oral liquids for a prolonged period or if clinical signs of dehydration are present. Correction of ketosis and vitamin deficiency should be strongly considered. Dextrose and vitamins should be included

in the therapy when prolonged vomiting is present, and thiamine should be administered before dextrose infusion to prevent Wernicke encephalopathy (99). Enteral tube feeding (nasogastric or nasoduodenal) should be initiated as the first-line treatment to provide nutritional support to the woman with hyperemesis gravidarum who is not responsive to medical therapy and cannot maintain her weight.

No randomized trials compare enteral with parenteral nutrition in women with nausea and vomiting of pregnancy who continue to lose weight despite antiemetic therapy. Several case reports and small series (100, 101) suggest that enteral tube feeding is well tolerated in pregnancy. In a retrospective study on nutritional treatment in pregnant women with hyperemesis, enteral tube feeding in 107 women was associated with sufficient maternal weight gain and good pregnancy outcomes (102). However, in a RCT of women with hyperemesis gravidarum allocated to enteral tube feeding for 7 days plus standard therapy versus standard therapy only (intravenous hydration, antiemetic medication and vitamin supplements), no differences were noted in infant birth weight or maternal weight gain (103). Yet the findings were limited because one half of women assigned to early enteral tube feeding either refused placement, failed insertion, or discontinued the intervention in fewer than 7 days. Total parenteral nutrition is a potentially life-threatening intervention because of associated sepsis and thromboembolic events. Adverse neonatal outcomes associated with the use of total parenteral nutrition in women with hyperemesis have been reported (104). Because life-threatening complications of parenteral nutrition have been described (41, 42, 105), enteral tube feeding initially should be used to provide nutritional support to a pregnant woman with hyperemesis who cannot maintain her weight.

Despite potential complications, total parenteral nutrition has been described for hyperemesis gravidarum for women who cannot tolerate enteral tube feedings. (41, 106). Peripherally inserted central catheters (PICCs) can be used to avoid some of the complications of central access (105), but they are still associated with significant morbidity (101, 107–109) and should be used only when enteral feeding is not possible. A 50% complication rate was found in a retrospective study of 52 pregnant women who received PICCs, including culture-proven and presumed line infection, cellulitis, mechanical line failure, pain necessitating discontinuation of PICCs, and superficial thrombophlebitis (107). A significant maternal complication rate (66.4%) associated with the use of PICCs also was noted in a retrospective study of 33 women with hyperemesis gravidarum and included infection, thromboembolism, bacteremia,

and sepsis (101). Similarly, another retrospective study of 66 pregnant women with hyperemesis who received PICCs for intravenous fluid, parenteral nutrition, and antibiotic administration also found complications in 55.9% of PICCs (109). The overall complication rate was 18.5 per 1,000 PICC days. Bacteremia was the most frequent major complication occurring in 20.2% of major complications. Thus, PICCs should not be used routinely in women with hyperemesis gravidarum given the significant complications associated with this intervention. Peripherally inserted central catheters should be used only as a last resort in the management of a woman with hyperemesis gravidarum because of the potential of severe maternal morbidity.

▶ When is hospitalization indicated?

When a woman cannot tolerate liquids without vomiting and has not responded to outpatient management, hospitalization for evaluation and treatment of dehydration and electrolyte imbalance is recommended. A RCT of 98 pregnant women assigned either to daily hydration obtained as an outpatient (day care) treatment or inpatient management of nausea and vomiting found that outpatient treatment resulted in fewer overnight hospital stays (110). Whereas a subsequent RCT of 53 pregnant women reported no differences in symptoms over 7 days between groups who received outpatient rehydration and antiemetic therapy versus inpatient care (111). After the patient has been hospitalized and a workup for other causes of severe vomiting has been undertaken, intravenous hydration, nutritional support, and modification of antiemetic therapy often can be accomplished at home. Nevertheless, the option of hospitalization for observation and further assessment should be preserved for patients who experience a change in vital signs or a change in mental status, continue to lose weight, and are refractory to treatment.

▶ Is there a role for behavioral interventions in treatment?

There is little evidence for a therapeutic effect of traditional behavioral intervention in hyperemesis gravidarum. There are case examples of effective medical hypnosis therapy used in women with hyperemesis gravidarum (112, 113). Hypnosis was found to be effective by the induced deep relaxation leading to decreased sympathetic nervous system arousal and by the response to hypnotic suggestion of symptom removal (113). A recent RCT of vitamin B_6 (pyridoxine) and mindfulness-based cognitive therapy versus vitamin B_6 (pyridoxine) alone in 86 women with moderate nausea and vomiting found that the vitamin B_6

(pyridoxine)–mindfulness-based cognitive therapy group had significant improvement in symptoms (114). The behavioral intervention was mindfulness-based cognitive therapy in eight sessions over a 3-week period. It is unclear if the improvement in symptoms was because of the mindfulness-based cognitive therapy alone or because of the additional contact received by the patients in the vitamin B_6 (pyridoxine)–mindfulness-based cognitive therapy group.

Summary of Recommendations

The following recommendations are based on good and consistent scientific evidence (Level A):

▶ Treatment of nausea and vomiting of pregnancy with vitamin B_6 (pyridoxine) alone or vitamin B_6 (pyridoxine) plus doxylamine in combination is safe and effective and should be considered first-line pharmacotherapy.

▶ The standard recommendation to take prenatal vitamins for 1 month before fertilization may reduce the incidence and severity of nausea and vomiting of pregnancy.

▶ The appropriate management of abnormal maternal thyroid tests attributable to gestational transient thyrotoxicosis, or hyperemesis gravidarum, or both, includes supportive therapy, and antithyroid drugs are not recommended.

The following recommendations are based on limited or inconsistent scientific evidence (Level B):

▶ Treatment of nausea and vomiting of pregnancy with ginger has shown some beneficial effects in reducing nausea symptoms and can be considered as a nonpharmacologic option.

▶ Treatment of severe nausea and vomiting of pregnancy or hyperemesis gravidarum with methylprednisolone may be efficacious in refractory cases; however, the risk profile of methylprednisolone suggests it should be a last-resort treatment.

The following recommendations are based primarily on consensus and expert opinion (Level C):

▶ Early treatment of nausea and vomiting of pregnancy may be beneficial to prevent progression to hyperemesis gravidarum.

▶ Intravenous hydration should be used for the patient who cannot tolerate oral liquids for a prolonged period or if clinical signs of dehydration are present.

Correction of ketosis and vitamin deficiency should be strongly considered. Dextrose and vitamins should be included in the therapy when prolonged vomiting is present, and thiamine should be administered before dextrose infusion to prevent Wernicke encephalopathy.

▶ Enteral tube feeding (nasogastric or nasoduodenal) should be initiated as the first-line treatment to provide nutritional support to the woman with hyperemesis gravidarum who is not responsive to medical therapy and cannot maintain her weight.

▶ Peripherally inserted central catheters should not be used routinely in women with hyperemesis gravidarum given the significant complications associated with this intervention. Peripherally inserted central catheters should be utilized only as a last resort in the management of a woman with hyperemesis gravidarum because of the potential of severe maternal morbidity.

References

1. Attard CL, Kohli MA, Coleman S, Bradley C, Hux M, Atanackovic G, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol 2002;186:S220–7. (Level II-2) ⇦

2. Piwko C, Koren G, Babashov V, Vicente C, Einarson TR. Economic burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol 2013;20: e149–60. (Level III) ⇦

3. O'Brien B, Naber S. Nausea and vomiting during pregnancy: effects on the quality of women's lives. Birth 1992;19:138–43. (Level III) ⇦

4. Brent R. Medical, social, and legal implications of treating nausea and vomiting of pregnancy. Am J Obstet Gynecol 2002;186:S262–6. (Level III) ⇦

5. Matthews A, Haas DM, O'Mathúna DP, Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD007575. DOI: 10.1002/14651858. CD007575.pub4. (Systematic Review) ⇦

6. Trogstad LI, Stoltenberg C, Magnus P, Skjaerven R, Irgens LM. Recurrence risk in hyperemesis gravidarum. BJOG 2005;112:1641–5. (Level II-3) ⇦

7. Koren G, Piwko C, Ahn E, Boskovic R, Maltepe C, Einarson A, et al. Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol 2005;25:241–4. (Level II-3) ⇦

8. Lacasse A, Rey E, Ferreira E, Morin C, Berard A. Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am J Obstet Gynecol 2008;198:71.e1–7. (Level II-2) ⇦

9. Gadsby R, Barnie-Adshead AM, Jagger C. Pregnancy nausea related to women's obstetric and personal histories. Gynecol Obstet Invest 1997;43:108–11. (Level II-2) ⇦

10. Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992;75:1333–7. (Level II-2) ⇐

11. Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. Obstet Gynecol 1985;66:612–6. (Level II-2) ⇐

12. Adams MM, Harlass FE, Sarno AP, Read JA, Rawlings JS. Antenatal hospitalization among enlisted servicewomen, 1987–1990. Obstet Gynecol 1994;84:35–9. (Level II-3) ⇐

13. Gazmararian JA, Petersen R, Jamieson DJ, Schild L, Adams MM, Deshpande AD, et al. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol 2002;100:94–100. (Level II-2) ⇐

14. Rodien P, Bremont C, Sanson ML, Parma J, Van Sande J, Costagliola S, et al. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. N Engl J Med 1998;339:1823–6. (Level III) ⇐

15. Innes AM, Seargeant LE, Balachandra K, Roe CR, Wanders RJ, Ruiter JP, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000;47:43–5. (Level III) ⇐

16. Malek NZ, Kalok A, Hanafiah ZA, Shah SA, Ismail NA. Association of transient hyperthyroidism and severity of hyperemesis gravidarum. Horm Mol Biol Clin Investig 2017;30(3). (Level II-3) ⇐

17. Thyroid disease in pregnancy. Practice Bulletin No. 148. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:996–1005. (Level III) ⇐

18. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017;27:315–89. (Level III) ⇐

19. Simpson SW, Goodwin TM, Robins SB, Rizzo AA, Howes RA, Buckwalter DK, et al. Psychological factors and hyperemesis gravidarum. J Womens Health Gend Based Med 2001;10:471–7. (Level II-2) ⇐

20. Flaxman SM, Sherman PW. Morning sickness: a mechanism for protecting mother and embryo. Q Rev Biol 2000;75:113–48. (Level III) ⇐

21. Yoshimura M, Hershman JM. Thyrotropic action of human chorionic gonadotropin. Thyroid 1995;5:425–34. (Level III) ⇐

22. Bernstein L, Pike MC, Lobo RA, Depue RH, Ross RK, Henderson BE. Cigarette smoking in pregnancy results in marked decrease in maternal hCG and oestradiol levels. Br J Obstet Gynaecol 1989;96:92–6. (Level II-2) ⇐

23. Depue RH, Bernstein L, Ross RK, Judd HL, Henderson BE. Hyperemesis gravidarum in relation to estradiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. Am J Obstet Gynecol 1987;156:1137–41. (Level II-2) ⇐

24. Goodwin TM. Nausea and vomiting of pregnancy: an obstetric syndrome. Am J Obstet Gynecol 2002;186:S184–9. (Level III) ⇐

25. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 1971;22:609–23. (Level I) ⇐

26. Whitehead SA, Andrews PL, Chamberlain GV. Characterisation of nausea and vomiting in early pregnancy: a survey of 1000 women. J Obstet Gynaecol 1992;12:364–9. (Level II-2) ⇐

27. Sherman PW, Flaxman SM. Nausea and vomiting of pregnancy in an evolutionary perspective. Am J Obstet Gynecol 2002;186:S190–7. (Level III) ⇐

28. Bogen JT. Neurosis: a MS-diagnosis. Perspect Biol Med 1994;37:263–74. (Level III) ⇐

29. Ezberci I, Guven ES, Ustuner I, Sahin FK, Hocaoglu C. Disability and psychiatric symptoms in hyperemesis gravidarum patients. Arch Gynecol Obstet 2014;289:55–60. (Level II-3) ⇐

30. Magtira A, Schoenberg FP, MacGibbon K, Tabsh K, Fejzo MS. Psychiatric factors do not affect recurrence risk of hyperemesis gravidarum. J Obstet Gynaecol Res 2015;41:512–6. (Level II-3) ⇐

31. Buckwalter JG, Simpson SW. Psychological factors in the etiology and treatment of severe nausea and vomiting in pregnancy. Am J Obstet Gynecol 2002;186:S210–4. (Level III) ⇐

32. Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy [published erratum appears in Br J Gen Pract 1993;43:325]. Br J Gen Pract 1993;43:245–8. (Level II-2) ⇐

33. Basso O, Olsen J. Sex ratio and twinning in women with hyperemesis or pre-eclampsia. Epidemiology 2001;12:747–9. (Level II-2) ⇐

34. Di Gangi S, Gizzo S, Patrelli TS, Saccardi C, D'Antona D, Nardelli GB. Wernicke's encephalopathy complicating hyperemesis gravidarum: from the background to the present. J Matern Fetal Neonatal Med 2012;25:1499–504. (Level III) ⇐

35. Togay-Isikay C, Yigit A, Mutluer N. Wernicke's encephalopathy due to hyperemesis gravidarum: an under-recognised condition. Aust N Z J Obstet Gynaecol 2001;41:453–6. (Level III) ⇐

36. Spruill SC, Kuller JA. Hyperemesis gravidarum complicated by Wernicke's encephalopathy. Obstet Gynecol 2002;99:875–7. (Level III) ⇐

37. Kim YH, Lee SJ, Rah SH, Lee JH. Wernicke's encephalopathy in hyperemesis gravidarum. Can J Ophthalmol 2002;37:37–8. (Level III) ⇐

38. Eroglu A, Kurkcuoglu C, Karaoglanoglu N, Tekinbas C, Cesur M. Spontaneous esophageal rupture following severe vomiting in pregnancy. Dis Esophagus 2002;15:242–3. (Level III) ⇐

39. Liang SG, Ooka F, Santo A, Kaibara M. Pneumomediastinum following esophageal rupture associated with hyperemesis gravidarum. J Obstet Gynaecol Res 2002;28:172–5. (Level III) ⇐

40. Nguyen N, Deitel M, Lacy E. Splenic avulsion in a pregnant patient with vomiting. Can J Surg 1995;38: 464–5. (Level III) ⇐

41. Russo-Stieglitz KE, Levine AB, Wagner BA, Armenti VT. Pregnancy outcome in patients requiring parenteral nutrition. J Matern Fetal Med 1999;8:164–7. (Level III) ⇐

42. Katz VL, Farmer R, York J, Wilson JD. Mycobacterium chelonae sepsis associated with long-term use of an intravenous catheter for treatment of hyperemesis gravidarum. A case report. J Reprod Med 2000; 45:581–4. (Level III) ⇐

43. Lamm SH. The epidemiological assessment of the safety and efficacy of Bendectin. In: Koren G, Bishai R, editors. Nausea and vomiting of pregnancy: state of the art 2000. Toronto (ON): Motherisk; 2000. p. 100–3. (Level III) ⇐

44. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health 1995;86:66–70. (Level III) ⇐

45. Mitchell-Jones N, Gallos I, Farren J, Tobias A, Bottomley C, Bourne T. Psychological morbidity associated with hyperemesis gravidarum: a systematic review and meta-analysis. BJOG 2017;124:20–30. (Systematic Review and Meta-analysis) ⇐

46. Hinkle SN, Mumford SL, Grantz KL, Silver RM, Mitchell EM, Sjaarda LA, et al. Association of nausea and vomiting during pregnancy with pregnancy loss: a secondary analysis of a randomized clinical trial. JAMA Intern Med 2016;176:1621–7. (Level I) ⇐

47. Veenendaal MV, van Abeelen AF, Painter RC, van der Post JA, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG 2011;118:1302–13. (Meta-analysis) ⇐

48. Jarnfelt-Samsioe A, Eriksson B, Waldenstrom J, Samsioe G. Some new aspects on emesis gravidarum. Relations to clinical data, serum electrolytes, total protein and creatinine. Gynecol Obstet Invest 1985;19:174–86. (Level II-2) ⇐

49. Weigel MM, Weigel RM. Nausea and vomiting of early pregnancy and pregnancy outcome. An epidemiological study. Br J Obstet Gynaecol 1989;96:1304–11. (Level II-2) ⇐

50. Chin RK, Lao TT. Low birth weight and hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 1988;28:179–83. (Level II-2) ⇐

51. Vandraas KF, Vikanes AV, Vangen S, Magnus P, Stoer NC, Grjibovski AM. Hyperemesis gravidarum and birth outcomes-a population-based cohort study of 2.2 million births in the Norwegian Birth Registry. BJOG 2013;120:1654–60. (Level II-2) ⇐

52. Czeizel AE, Dudas I, Fritz G, Tecsoi A, Hanck A, Kunovits G. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet 1992;251:181–5. (Level I) ⇐

53. Emelianova S, Mazzotta P, Einarson A, Koren G. Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. Clin Invest Med 1999;22:106–10. (Level II-2) ⇐

54. Neural tube defects. ACOG Practice Bulletin No. 187. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e279–90. (Level III) ⇐

55. Bischoff SC, Renzer C. Nausea and nutrition. Auton Neurosci 2006;129:22–7. (Level III) ⇐

56. Power ML, Holzman GB, Schulkin J. A survey on the management of nausea and vomiting in pregnancy by obstetrician/gynecologists. Prim Care Update Ob Gyns 2001;8:69–72. (Level III) ⇐

57. Jednak MA, Shadigian EM, Kim MS, Woods ML, Hooper FG, Owyang C, et al. Protein meals reduce nausea and gastric slow wave dysrhythmic activity in first trimester pregnancy. Am J Physiol 1999;277:G855–61. (Level II-3) ⇐

58. Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J 2014;13:20,2891–13–20. (Meta-analysis) ⇐

59. McParlin C, O'Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. JAMA 2016;316:1392–401. (Systematic Review) ⇐

60. Roscoe JA, Matteson SE. Acupressure and acustimulation bands for control of nausea: a brief review. Am J Obstet Gynecol 2002;186:S244–7. (Level III) ⇐

61. Maltepe C, Koren G. Preemptive treatment of nausea and vomiting of pregnancy: results of a randomized controlled trial. Obstet Gynecol Int 2013;2013:809787. (Level I) ⇐

62. Reichmann JP, Kirkbride MS. Reviewing the evidence for using continuous subcutaneous metoclopramide and ondansetron to treat nausea & vomiting during pregnancy. Manag Care 2012;21:44–7. (Level III) ⇐

63. Klauser CK, Fox NS, Istwan N, Rhea D, Rebarber A, Desch C, et al. Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. Am J Perinatol 2011;28:715–21. (Level II-3) ⇐

64. Reichmann JP, Kirkbride MS. Nausea and vomiting of pregnancy: cost effective pharmacologic treatments. Manag Care 2008;17:41–5. (Cost-analysis) ⇐

65. Sahakian V, Rouse D, Sipes S, Rose N, Niebyl J. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol 1991;78:33–6. (Level I) ⇐

66. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1995;173:881–4. (Level I) ⇐

67. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 1994;50:27–37. (Meta-analysis) ⇐

68. Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and birth defects. II: Ecological analyses. Birth Defects Res A Clin Mol Teratol 2003;67:88–97. (Level II-3) ⇐

69. Slaughter SR, Hearns-Stokes R, van der Vlugt T, Joffe HV. FDA approval of doxylamine-pyridoxine therapy for use in pregnancy. N Engl J Med 2014;370: 1081–3. (Level III) ⇐

70. Koren G, Clark S, Hankins GD, Caritis SN, Miodovnik M, Umans JG, et al. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 2010;203:571.e1–7. (Level I) ⇐

71. Koren G, Clark S, Hankins GD, Caritis SN, Umans JG, Miodovnik M, et al. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. BMC Pregnancy Childbirth 2015;15:59. (Level I) ⇐

72. Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (Diclegis(R)/Diclectin (R)) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs 2014;16: 199–211. (Level III) ⇐

73. Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol 2002;186:S256–61. (Level III) ⇐

74. Tan PC, Khine PP, Vallikkannu N, Omar SZ. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol 2010;115:975–81. (Level I) ⇐

75. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977;15:57–64. (Level II-2) ⇐

76. Bustos M, Venkataramanan R, Caritis S. Nausea and vomiting of pregnancy—what's new? Auton Neurosci 2017;202:62–72. (Level III) ⇐

77. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. National Birth Defects Prevention Study. Am J Obstet Gynecol 2011;205:51.e1–e8. (Level II-2) ⇐

78. Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol 2014;123:1272–9. (Level I) ⇐

79. Kashifard M, Basirat Z, Kashifard M, Golsorkhtabar-Amiri M, Moghaddamnia A. Ondansetrone or metoclopramide? Which is more effective in severe nausea and vomiting of pregnancy? A randomized trial double-blind study. Clin Exp Obstet Gynecol 2013;40:127–30. (Level I) ⇐

80. Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. Obstet Gynecol 2014;124:735–42. (Level I) ⇐

81. Pasternak B, Svanstrom H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes [published erratum appears in N Engl J Med 2013;368:2146]. N Engl J Med 2013;368:814–23. (Level II-3) ⇐

82. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med 2014;64:19–25.e6. (Level III) ⇐

83. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2012;94:22–30. (Level II-2) ⇐

84. Danielsson B, Wikner BN, Kallen B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol 2014;50:134–7. (Level II-2) ⇐

85. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004;111:940–3. (Level II-2) ⇐

86. Carstairs SD. Ondansetron use in pregnancy and birth defects: a systematic review. Obstet Gynecol 2016;127: 878–83. (Level III) ⇐

87. Safari HR, Fassett MJ, Souter IC, Alsulyman OM, Goodwin TM. The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. Am J Obstet Gynecol 1998;179:921–4. (Level I) ⇐

88. Yost NP, McIntire DD, Wians FH Jr, Ramin SM, Balko JA, Leveno KJ. A randomized, placebo-controlled trial of corticosteroids for hyperemesis due to pregnancy. Obstet Gynecol 2003;102:1250–4. (Level I) ⇐

89. Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD010607. DOI: 10.1002/14651858.CD010607.pub2. (Systematic Review) ⇐

90. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999;86:242–4. (Level II-2) ⇐

91. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385–92. (Meta-analysis) ⇐

92. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998;58:2–5. (Level II-2) ⇐

93. Shepard TH, Brent RL, Friedman JM, Jones KL, Miller RK, Moore CA, et al. Update on new developments in the study of human teratogens. Teratology 2002;65:153–61. (Level III) ⇐

94. Niemeijer MN, Grooten IJ, Vos N, Bais JM, van der Post JA, Mol BW, et al. Diagnostic markers for hyperemesis gravidarum: a systematic review and meta-analysis. Am J Obstet Gynecol 2014;211:150.e1–15. (Meta-analysis) ⇐

95. Kallen BA. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed during

pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 96:63–8. (Level II-2) ⇐

96. Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476–81. (Level II-2) ⇐

97. Jacoby EB, Porter KB. Helicobacter pylori infection and persistent hyperemesis gravidarum. Am J Perinatol 1999;16:85–8. (Level III) ⇐

98. Goodwin TM, Montoro M, Mestman JH. Transient hyperthyroidism and hyperemesis gravidarum: clinical aspects. Am J Obstet Gynecol 1992;167:648–52. (Level II-2) ⇐

99. Giugale LE, Young OM, Streitman DC. Iatrogenic Wernicke encephalopathy in a patient with severe hyperemesis gravidarum. Obstet Gynecol 2015;125:1150–2. (Level III) ⇐

100. Hsu JJ, Clark-Glena R, Nelson DK, Kim CH. Nasogastric enteral feeding in the management of hyperemesis gravidarum. Obstet Gynecol 1996;88:343–6. (Level III) ⇐

101. Holmgren C, Aagaard-Tillery KM, Silver RM, Porter TF, Varner M. Hyperemesis in pregnancy: an evaluation of treatment strategies with maternal and neonatal outcomes. Am J Obstet Gynecol 2008;198:56.e1–4. (Level II-3) ⇐

102. Stokke G, Gjelsvik BL, Flaatten KT, Birkeland E, Flaatten H, Trovik J. Hyperemesis gravidarum, nutritional treatment by nasogastric tube feeding: a 10-year retrospective cohort study. Acta Obstet Gynecol Scand 2015;94:359–67. (Level II-3) ⇐

103. Grooten IJ, Koot MH, van der Post JA, Bais JM, Ris-Stalpers C, Naaktgeboren C, et al. Early enteral tube feeding in optimizing treatment of hyperemesis gravidarum: the Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding (MOTHER) randomized controlled trial. Am J Clin Nutr 2017;106:812–20. (Level I) ⇐

104. Folk JJ, Leslie-Brown HF, Nosovitch JT, Silverman RK, Aubry RH. Hyperemesis gravidarum: outcomes and complications with and without total parenteral nutrition. J Reprod Med 2004;49:497–502. (Level II-3) ⇐

105. Greenspoon JS, Masaki DI, Kurz CR. Cardiac tamponade in pregnancy during central hyperalimentation. Obstet Gynecol 1989;73:465–6. (Level III) ⇐

106. Zibell-Frisk D, Jen KL, Rick J. Use of parenteral nutrition to maintain adequate nutritional status in hyperemesis gravidarum. J Perinatol 1990;10:390–5. (Level II-2) ⇐

107. Ogura JM, Francois KE, Perlow JH, Elliott JP. Complications associated with peripherally inserted central catheter use during pregnancy. Am J Obstet Gynecol 2003;188:1223–5. (Level III) ⇐

108. Paranyuk Y, Levine G, Figueroa R. Candida septicemia in a pregnant woman with hyperemesis receiving parenteral nutrition. Obstet Gynecol 2006;107:535–7. (Level III) ⇐

109. Cape AV, Mogensen KM, Robinson MK, Carusi DA. Peripherally inserted central catheter (PICC) complications during pregnancy. JPEN J Parenter Enteral Nutr 2014;38:595–601. (Level II-3) ⇐

110. McCarthy FP, Murphy A, Khashan AS, McElroy B, Spillane N, Marchocki Z, et al. Day care compared with inpatient management of nausea and vomiting of pregnancy: a randomized controlled trial. Obstet Gynecol 2014;124:743–8. (Level I) ⇐

111. McParlin C, Carrick-Sen D, Steen IN, Robson SC. Hyperemesis in Pregnancy Study: a pilot randomised controlled trial of midwife-led outpatient care. Eur J Obstet Gynecol Reprod Biol 2016;200:6–10. (Level I) ⇐

112. Madrid A, Giovannoli R, Wolfe M. Treating persistent nausea of pregnancy with hypnosis: four cases. Am J Clin Hypn 2011;54:107–15. (Level III) ⇐

113. Simon EP, Schwartz J. Medical hypnosis for hyperemesis gravidarum. Birth 1999;26:248–54. (Level III) ⇐

114. Faramarzi M, Yazdani S, Barat S. A RCT of psychotherapy in women with nausea and vomiting of pregnancy. Hum Reprod 2015;30:2764–73. (Level l) ⇐

The MEDLINE database, the Cochrane Library, and ACOG's own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 2000 and September 2017. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician–gynecologists were used.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

I   Evidence obtained from at least one properly designed randomized controlled trial.
II-1 Evidence obtained from well-designed controlled trials without randomization.
II-2 Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.
II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
III   Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A—Recommendations are based on good and consistent scientific evidence.

Level B—Recommendations are based on limited or inconsistent scientific evidence.

Level C—Recommendations are based primarily on consensus and expert opinion.